Antibiotics to Need Central Approval Before Manufacture: How India Plans to Fight Drug Resistance
The Union Ministry of Health and Family Welfare has published draft changes to India's drug rules to bring antimicrobials (medicines that kill or stop germs, such as antibiotics) under tighter central control.
The main proposal adds "antimicrobials" to the definition of a "new drug" in the New Drugs and Clinical Trials Rules, 2019. The word is to be inserted right after "monoclonal anti-body" in that definition.
If this becomes final, a company must first get permission from the Central Licensing Authority (the Drugs Controller General of India) before it can apply to a state drug regulator for a licence to make an antimicrobial.
The ministry said some licences for antimicrobial products were given without proper checks, such as bioavailability/bioequivalence studies (tests that show the medicine reaches the blood in the right amount) and stability studies (tests that show the medicine stays effective until its expiry date). Poor-quality antimicrobials can help germs become resistant.
Licences already issued will stay valid, and existing holders will not need fresh central permission. The plan also includes a separate licence for wholesalers who trade in bulk drugs (the raw active ingredients used to make medicines), so that this trade can be tracked better.
The draft, dated 6 November 2026, is open for public objections and suggestions for 30 days before the government decides on the final rules.
New Drugs and Clinical Trials Rules, 2019
The New Drugs and Clinical Trials Rules, 2019 (often called the NDCT Rules) are India's main rulebook for two things: approving new medicines and running clinical trials (tests of medicines on human volunteers). They decide who must give permission, what proof a company must show, how fast the regulator must reply, and what happens if a trial volunteer is hurt. The central government made these rules under the Drugs and Cosmetics Act, 1940, and they are applied by the Central Drugs Standard Control Organisation (CDSCO).
The draft adds "antimicrobials" to group 5 of the new drug definition, right after "monoclonal anti-body". Group 5 products are always deemed new drugs, so every antimicrobial would need CLA permission, with data such as BA/BE and stability studies, before a state could license its manufacture. This shifts the first check for antibiotics from the states to the Centre.
Antimicrobial Resistance (AMR): A Global Health Priority
Antimicrobial resistance (AMR) happens when bacteria, viruses, fungi or parasites change over time and stop responding to the medicines that used to kill them. Common infections then become hard, costly or impossible to treat. The main drivers are overuse and misuse of antimicrobials in people and animals, poor infection control, and poor-quality medicines that give germs a weak dose they can survive and learn from.
The ministry says substandard antimicrobials, licensed without bioequivalence and stability checks, can add to AMR. Making central approval compulsory for every antimicrobial is a supply-side step: it aims to ensure that only medicines of proven quality reach patients.
Central Drugs Standard Control Organisation (CDSCO)
The Central Drugs Standard Control Organisation (CDSCO) is India's national drug regulator, working under the Directorate General of Health Services in the Ministry of Health and Family Welfare. It is headed by the Drugs Controller General of India (DCGI). Under the Drugs and Cosmetics Act, 1940, India follows a split system: the Centre approves new drugs, clinical trials and imports, while state drug controllers license the manufacture, sale and distribution of medicines.
The draft moves the first approval for antimicrobials from state regulators to the CDSCO, and a separate bulk-drug wholesale licence would let regulators trace raw ingredients from importer to factory. Both steps strengthen central oversight in a system where quality has varied from state to state.
- Draft amendment to the New Drugs and Clinical Trials Rules, 2019, dated 6 November 2026; 30 days for public objections and suggestions
- Proposal: insert "antimicrobials" after "monoclonal anti-body" in Rule 2(1)(w)(v), the group of products always deemed new drugs
- Effect: prior permission from the Central Licensing Authority (DCGI) before applying to a State Licensing Authority for a manufacturing licence
- Existing manufacturing licences for antimicrobials remain valid
- Reason cited: licences granted without mandatory bioavailability/bioequivalence and stability studies
- A separate licence for wholesale trade in bulk drugs is also proposed
- NDCT Rules notified 19 March 2019 (G.S.R. 227(E)); new drugs in groups 1 to 3 stay new for 4 years
- UN AMR declaration (26 September 2024): 10% cut in AMR-associated deaths by 2030 from a 2019 baseline of 4.95 million
- NAP-AMR 2.0 covers 2025 to 2029